Clay Siegall is tackling the Most feared killer disease

A condition like heart disease is officially known to be the most dreaded killer, but also everybody is scared of discovering they have cancer. Nowadays everybody knows somebody who has succumbed from cancer or who currently has cancer. The disease has affected almost anybody in your surrounding can be either your neighbor or a member of your family. But the fortunately enough the research community of medicine are relentlessly finding ways to cure and prevent cancer.

 

Clay B. Siegell is one of the best-learned scholars when it comes to cancer research. Mr.Siegell is the Chairman, co-founder, Chief Executive Officer and President of Seattle Genetics in Bothell Washington. Siegell served for the National Cancer Institute before launching his company in 1998 named Seattle Genetics. The Institute he worked for was known as Bristol-Myers Pharmaceutical Research Institute.

 

While at the Institute, Bristol-Myers he started working on the thesis of utilizing antibody conjugates to fight cancer. The antibodies known as monoclonal are within our body’s immune system. The antibodies have the capability to identify cancer cells, but they do not have strength to destroy the cells. Mr. Clay’s idea is to accompany some capable destroyer to the antibodies. The main aim Siegell comes up with Seattle Genetics was to specialize in ADC solutions to fight cancer. Mr. Siegell company has been developing all through since its establishment, and now the company is ranked in the leading positions. An interesting moment was in 2011 where the company was approved by Food and Drug Administration to dispose of off their first drug, ADCETRIS to the public. The drug is based on the latest technology of ADC at the time.

 

The firm has also made some partnership with companies like Genetech (Roche) Abbvie GlaxoSmithKline and Pfizer. The collaboration with various companies has pumped over $340 million in revenue alone. In 2001 Seattle Genetic went in public, and since then they have raised $1.1 billion.